Insomnia drug approved for extended use

Circadin is a synthetic version of melatonin, the sleep-inducing hormone produced by the pineal gland

Circadin (melatonin) can now be prescribed for up to 13 weeks. It was previously approved only as a 3-week course of treatment.

The 2mg prolonged-release tablet is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients aged 55 or over.

In a study in this setting, a subgroup of patients aged between 65 and 80 years fell asleep significantly more quickly following treatment with prolonged-release melatonin for up to 26 weeks, than after receiving placebo.

View Circadin drug record

Further information: Lundbeck

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Deleted products - live tracker

EXCLUSIVE TO SUBSCRIBERS See the latest products removed...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Pregnant woman having an ultrasound scan with a female sonographer

Valproate prescribing: plan for new regulatory measures without delay, instructs MHRA

A National Patient Safety Alert (NatPSA) has been issued...

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...